Dexi Wu

905 total citations
27 papers, 645 citations indexed

About

Dexi Wu is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Dexi Wu has authored 27 papers receiving a total of 645 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cardiology and Cardiovascular Medicine, 7 papers in Molecular Biology and 5 papers in Surgery. Recurrent topics in Dexi Wu's work include Cardiovascular Function and Risk Factors (9 papers), Cardiac Arrhythmias and Treatments (8 papers) and Heart Failure Treatment and Management (8 papers). Dexi Wu is often cited by papers focused on Cardiovascular Function and Risk Factors (9 papers), Cardiac Arrhythmias and Treatments (8 papers) and Heart Failure Treatment and Management (8 papers). Dexi Wu collaborates with scholars based in China, United States and Denmark. Dexi Wu's co-authors include P Denes, F Amat-y-Leon, Kenneth M. Rosen, Christopher R.C. Wyndham, Ramesh C. Dhingra, Raymond J. Pietras, Yugang Dong, Ruben Chuquimia, Chen Liu and Ruicong Xue and has published in prestigious journals such as Circulation, Annals of Internal Medicine and Circulation Research.

In The Last Decade

Dexi Wu

26 papers receiving 586 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dexi Wu China 15 531 164 75 53 36 27 645
Ting‐Tse Lin Taiwan 14 365 0.7× 122 0.7× 46 0.6× 46 0.9× 38 1.1× 72 589
Maria Domenica Guglielmi Italy 12 309 0.6× 78 0.5× 90 1.2× 48 0.9× 24 0.7× 24 530
Hassan Kattach United Kingdom 10 449 0.8× 132 0.8× 123 1.6× 84 1.6× 43 1.2× 17 641
Jason L. Guichard United States 13 346 0.7× 84 0.5× 149 2.0× 54 1.0× 22 0.6× 27 565
Pingshuan Dong China 13 227 0.4× 98 0.6× 77 1.0× 43 0.8× 37 1.0× 45 467
J.-P. Baguet France 10 373 0.7× 140 0.9× 32 0.4× 23 0.4× 25 0.7× 18 544
Yuhei Shiga Japan 13 302 0.6× 163 1.0× 44 0.6× 48 0.9× 126 3.5× 91 509
Takeshi Tobiume Japan 14 340 0.6× 146 0.9× 125 1.7× 71 1.3× 36 1.0× 38 585
Hillary Mulder United States 9 241 0.5× 99 0.6× 25 0.3× 54 1.0× 16 0.4× 15 376

Countries citing papers authored by Dexi Wu

Since Specialization
Citations

This map shows the geographic impact of Dexi Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dexi Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dexi Wu more than expected).

Fields of papers citing papers by Dexi Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dexi Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dexi Wu. The network helps show where Dexi Wu may publish in the future.

Co-authorship network of co-authors of Dexi Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Dexi Wu. A scholar is included among the top collaborators of Dexi Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dexi Wu. Dexi Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhu, Wengen, et al.. (2024). Real-world evidence of direct oral anticoagulants in patients with atrial fibrillation and cancer: A meta-analysis. IJC Heart & Vasculature. 55. 101512–101512.
2.
Zhang, Xuebin, Yu Duan, Xiao Zhang, et al.. (2023). Adipsin alleviates cardiac microvascular injury in diabetic cardiomyopathy through Csk-dependent signaling mechanism. BMC Medicine. 21(1). 197–197. 20 indexed citations
3.
Man, Wanrong, Zhenyu Xiong, Jing Gu, et al.. (2022). Exosomes derived from pericardial adipose tissues attenuate cardiac remodeling following myocardial infarction by Adipsin-regulated iron homeostasis. Frontiers in Cardiovascular Medicine. 9. 1003282–1003282. 22 indexed citations
4.
Liang, Weihao, Yuzhong Wu, Ruicong Xue, et al.. (2021). C2HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial. BMC Medicine. 19(1). 44–44. 12 indexed citations
5.
Zhu, Wengen, Yuzhong Wu, Weihao Liang, et al.. (2021). Living Alone and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Psychosomatic Medicine. 83(5). 470–476. 8 indexed citations
6.
He, Xin, Bin Dong, Ruicong Xue, et al.. (2021). Effect of Aggressive Diuresis in Acute Heart Failure with Reduced and Preserved Ejection Fraction. ESC Heart Failure. 8(4). 3248–3256. 10 indexed citations
7.
Wu, Yuzhong, Weihao Liang, Ruicong Xue, et al.. (2021). Usefulness of CHADS2, R2CHADS2, and CHA2DS2-VASc Scores for Predicting Incident Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction Patients. ESC Heart Failure. 8(2). 1369–1377. 13 indexed citations
8.
Zhu, Wengen, Shilan Chen, Dexi Wu, et al.. (2021). Comparative Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients. Stroke. 52(4). 1225–1233. 38 indexed citations
9.
Liang, Weihao, Xin He, Dexi Wu, et al.. (2021). Prognostic Implication of Liver Function Tests in Heart Failure With Preserved Ejection Fraction Without Chronic Hepatic Diseases: Insight From TOPCAT Trial. Frontiers in Cardiovascular Medicine. 8. 618816–618816. 18 indexed citations
10.
Liu, Jian, Weihao Liang, Xin He, et al.. (2020). Major depression and clinical outcomes in patients with heart failure with preserved ejection fraction. European Journal of Clinical Investigation. 51(3). e13401–e13401. 9 indexed citations
11.
12.
Wu, Yuzhong, Wengen Zhu, Xin He, et al.. (2020). Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial. British Journal of General Practice. 71(702). e62–e70. 17 indexed citations
13.
Dong, Bin, Xin He, Ruicong Xue, et al.. (2020). Clinical Implication of Pulmonary Hospitalization in Heart Failure with Preserved Ejection Fraction: From the TOPCAT. ESC Heart Failure. 7(6). 3801–3809. 1 indexed citations
14.
15.
Zhao, Jingjing, Chongyu Zhang, Jian Liu, et al.. (2018). Prognostic Significance of Serum Cysteine-Rich Protein 61 in Patients with Acute Heart Failure. Cellular Physiology and Biochemistry. 48(3). 1177–1187. 18 indexed citations
16.
Xiao, Ying, et al.. (2016). Long-term treatment of spontaneously hypertensive rats with PD123319 and electrophysiological remodeling of left ventricular myocardium. Naunyn-Schmiedeberg s Archives of Pharmacology. 389(12). 1333–1340. 1 indexed citations
17.
Li, Yi, Daya Yang, Lihe Lu, et al.. (2015). Thermodilutional Confirmation of Coronary Microvascular Dysfunction in Patients With Recurrent Angina After Successful Percutaneous Coronary Intervention. Canadian Journal of Cardiology. 31(8). 989–997. 22 indexed citations
18.
Liu, Chen, Ruicong Xue, Dexi Wu, et al.. (2014). REDD1 attenuates cardiac hypertrophy via enhancing autophagy. Biochemical and Biophysical Research Communications. 454(1). 215–220. 31 indexed citations
19.
Amat-y-Leon, F, et al.. (1977). Sites of Conduction Disease in Aortic Stenosis. Annals of Internal Medicine. 87(3). 275–280. 34 indexed citations
20.
Wu, Dexi, P Denes, Ramesh C. Dhingra, Christopher R.C. Wyndham, & Kenneth M. Rosen. (1975). Determinants of fast- and slow-pathway conduction in patients with dual atrioventricular nodal pathways.. Circulation Research. 36(6). 782–790. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ting‐Tse Lin Breakdown of academic impact, for papers by Maria Domenica Guglielmi Breakdown of academic impact, for papers by Hassan Kattach Breakdown of academic impact, for papers by Jason L. Guichard Breakdown of academic impact, for papers by Pingshuan Dong Breakdown of academic impact, for papers by J.-P. Baguet Breakdown of academic impact, for papers by Yuhei Shiga Breakdown of academic impact, for papers by Takeshi Tobiume Breakdown of academic impact, for papers by Hillary Mulder
Rankless by CCL
2026